Key Highlights
- Capricor Therapeutics (NASDAQ: CAPR) signed a lease for approximately 171,000 rentable square feet in San Diego to serve as its new headquarters and manufacturing hub.
- The initial monthly base rent is set at $5.60 per rentable square foot, totaling approximately $958,000, with annual increases of 3.0%.
- The agreement includes an 18‑month full rent abatement, followed by six months of partial abatement on approximately 128,068 rentable square feet.
- The lease may terminate if Capricor fails to secure FDA approval for Deramiocel by December 31, 2026.
Lease Agreement Announced
Capricor Therapeutics (NASDAQ: CAPR) has finalized a lease for a new facility in San Diego, marking a significant expansion of its operational footprint. The space, spanning approximately 171,000 rentable square feet, will house the company’s headquarters, manufacturing cleanrooms, research labs, and administrative offices. The move reflects Capricor’s growth trajectory as it advances its pipeline, particularly its Duchenne muscular dystrophy therapy, Deramiocel.
Facility and Financial Terms
The leased property is located at 9625 Towne Centre Drive in San Diego. Under the terms, Capricor will pay an initial monthly base rent of $5.60 per rentable square foot, equating to approximately $958,000 per month. Annual rent increases of 3.0% are built into the agreement, ensuring escalating costs over the lease’s duration.
Rent Abatement Structure
Capricor secured favorable lease concessions, including an 18‑month period of full base rent abatement starting upon the rent commencement date. Following this, the company will receive an additional six months of partial abatement, during which base rent will apply to approximately 128,068 rentable square feet of the total space. After this phase, rent will cover the entire premises.
The landlord will also contribute a tenant improvement allowance to support build‑out costs.
FDA Contingency Clause
The lease includes a critical contingency tied to regulatory approval. If Capricor does not receive FDA approval for Deramiocel by December 31, 2026, either party may terminate the agreement with written notice within five business days. This clause underscores the high‑stakes nature of the company’s clinical and commercial strategy, linking its real estate commitments directly to its therapeutic pipeline.
Lease Timeline and Commencement
The lease term is set to begin on the earlier of two dates: either when Capricor satisfies or waives its FDA‑related lease contingency, or December 31, 2026. Rent payments will commence twelve months after this start date, and the lease will continue for a multi‑year period aligned with Capricor’s operational and regulatory milestones.
Operational Responsibilities
Capricor will assume customary obligations associated with occupying the premises, including payment of property taxes, acquisition of building insurance, and oversight of routine maintenance and operating expenses. These responsibilities give the company greater control over the facility’s upkeep and customization.
Strategic Implications for Investors
The lease signals Capricor’s confidence in its near‑term regulatory outlook and long‑term growth. By securing a large, modern facility, the company is preparing for potential commercialization of Deramiocel while expanding its research and development infrastructure. The financial terms, including rent abatements, offer some near‑term relief but commit Capricor to significant long‑term obligations.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...